<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02397954</url>
  </required_header>
  <id_info>
    <org_study_id>OPH2002</org_study_id>
    <nct_id>NCT02397954</nct_id>
  </id_info>
  <brief_title>A Study to Establish the Safety and Tolerability of Zimura® (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)</brief_title>
  <official_title>A Phase 2a Study to Establish the Safety and Tolerability of Zimura® (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ophthotech Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ophthotech</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the safety and tolerability of Zimura™
      intravitreous injection in combination with anti-vascular endothelial growth factor (VEGF)
      therapy in subjects with Idiopathic Polypoidal Choroidal Vasculopathy (IPCV).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment experienced (Prior treatment with anti-VEGF monotherapy of ≥8 injections in the
      previous twelve (12) months) subjects of either gender aged 50 years or above with a
      diagnosis of IPCV, will receive 3 monthly (Q4W) intravitreal injections of Zimura™ (1 mg/eye)
      in combination with anti-VEGF therapy (Avastin® 1.25 mg/eye or Lucentis® 0.5 mg/eye or Eylea®
      2 mg/eye).

      Safety endpoints include visual acuity loss (proportion of subjects with &gt;15 letter loss at
      Month 3), ophthalmic adverse events (AEs), systemic adverse events (AEs), change in total
      retinal thickness (SD-OCT) at Month 3, regression and/or elimination of polyps at Month 3
      compared to screening as measured by indocyanine green angiography (ICGA), and laboratory
      values.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With &gt;15 ETDRS Letter Loss at Month 3</measure>
    <time_frame>3 Months</time_frame>
    <description>Number of participants with &gt;15 ETDRS letter loss (with calculated percentage)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Ophthalmic Adverse Events</measure>
    <time_frame>3 months</time_frame>
    <description>Number of Participants with Ophthalmic Adverse Events (with calculated percentage)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Systemic Adverse Events</measure>
    <time_frame>3 months</time_frame>
    <description>Number of Participants with Systemic Adverse Events (with calculated percentage)</description>
  </primary_outcome>
  <other_outcome>
    <measure>Mean Change in Central Subfield Retinal Thickness (SD-OCT) From Baseline at Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
    <description>Mean change in central subfield retinal thickness from baseline at Month 3 as measured by SD-OCT</description>
  </other_outcome>
  <other_outcome>
    <measure>Regression and/or Elimination of Polyps at Month 3</measure>
    <time_frame>Baseline and Month 3</time_frame>
    <description>Regression and/or Elimination of Polyps from baseline to Month 3</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Idiopathic Polypoidal Choroidal Vasculopathy</condition>
  <arm_group>
    <arm_group_label>Zimura + Anti-VEGF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive monthly intravitreous injections of Zimura in combination with either Lucentis, Avastin or Eylea.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zimura</intervention_name>
    <description>Subjects will receive monthly intravitreous injections of Zimura in combination with Lucentis, Avastin or Eylea.</description>
    <arm_group_label>Zimura + Anti-VEGF</arm_group_label>
    <other_name>Avastin</other_name>
    <other_name>Eylea</other_name>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects of either gender aged ≥ 50 years

          -  Diagnosis of IPCV

          -  Treatment-experienced defined as prior treatment with anti-VEGF mono therapy of ≥ 8
             injections in the previous twelve (12) months

        Exclusion Criteria:

          -  Any intraocular surgery or thermal laser within three (3) months of trial entry

          -  Any prior thermal laser in the macular region, regardless of indication

          -  Any ocular or periocular infection in the twelve (12) weeks prior to entry

          -  History of any of the following conditions or procedures in the study eye:
             Rhegmatogenous retinal detachment, pars plana vitrectomy, filtering surgery (e.g.
             trabeculectomy), glaucoma drainage device, corneal transplant

          -  Previous therapeutic radiation in the region of the study eye

          -  A diagnosis of diabetic retinopathy (presence of microaneurysms or any vasculopathy
             and/or leakage from retinal vasculature in a subject with diabetes mellitus)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>March 19, 2015</study_first_submitted>
  <study_first_submitted_qc>March 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2015</study_first_posted>
  <results_first_submitted>January 2, 2019</results_first_submitted>
  <results_first_submitted_qc>January 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 23, 2019</results_first_posted>
  <disposition_first_submitted>April 4, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>April 4, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 5, 2017</disposition_first_posted>
  <last_update_submitted>June 18, 2019</last_update_submitted>
  <last_update_submitted_qc>June 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>idiopathic polypoidal choroidal vasculopathy</keyword>
  <keyword>IPCV</keyword>
  <keyword>Zimura™</keyword>
  <keyword>Avastin®</keyword>
  <keyword>Eylea®</keyword>
  <keyword>Lucentis®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share individual participant data at this time</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Zimura + Anti-VEGF</title>
          <description>Zimura 1mg/eye intravitreal injection + Anti-vascular endothelial growth factor (VEGF) (Avastin 1.25mg/eye or Lucentis 0.5mg/eye or Eylea 2mg/eye) intravitreal injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zimura + Anti-VEGF</title>
          <description>Zimura 1mg/eye intravitreal injection + Anti-VEGF (Avastin 1.25mg/eye or Lucentis 0.5mg/eye or Eylea 2mg/eye) intravitreal injection</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.5" spread="6.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <title>Adults 50-65</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Adults &gt;65-75</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Adults &gt;75</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With &gt;15 ETDRS Letter Loss at Month 3</title>
        <description>Number of participants with &gt;15 ETDRS letter loss (with calculated percentage)</description>
        <time_frame>3 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zimura + Anti-VEGF</title>
            <description>Zimura 1mg/eye intravitreal injection + Anti-VEGF (Avastin 1.25mg/eye or Lucentis 0.5mg/eye or Eylea 2mg/eye) intravitreal injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With &gt;15 ETDRS Letter Loss at Month 3</title>
          <description>Number of participants with &gt;15 ETDRS letter loss (with calculated percentage)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Ophthalmic Adverse Events</title>
        <description>Number of Participants with Ophthalmic Adverse Events (with calculated percentage)</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zimura + Anti-VEGF</title>
            <description>Zimura 1mg/eye intravitreal injection + Anti-VEGF (Avastin 1.25mg/eye or Lucentis 0.5mg/eye or Eylea 2mg/eye) intravitreal injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ophthalmic Adverse Events</title>
          <description>Number of Participants with Ophthalmic Adverse Events (with calculated percentage)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Systemic Adverse Events</title>
        <description>Number of Participants with Systemic Adverse Events (with calculated percentage)</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zimura + Anti-VEGF</title>
            <description>Zimura 1mg/eye intravitreal injection + Anti-VEGF (Avastin 1.25mg/eye or Lucentis 0.5mg/eye or Eylea 2mg/eye) intravitreal injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Systemic Adverse Events</title>
          <description>Number of Participants with Systemic Adverse Events (with calculated percentage)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Change in Central Subfield Retinal Thickness (SD-OCT) From Baseline at Month 3</title>
        <description>Mean change in central subfield retinal thickness from baseline at Month 3 as measured by SD-OCT</description>
        <time_frame>Baseline and Month 3</time_frame>
        <population>Limited sample size; all study participants were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Zimura + Anti-VEGF</title>
            <description>Zimura 1mg/eye intravitreal injection + Anti-VEGF (Avastin 1.25mg/eye or Lucentis 0.5mg/eye or Eylea 2mg/eye) intravitreal injection</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Central Subfield Retinal Thickness (SD-OCT) From Baseline at Month 3</title>
          <description>Mean change in central subfield retinal thickness from baseline at Month 3 as measured by SD-OCT</description>
          <population>Limited sample size; all study participants were included in the analysis.</population>
          <units>μm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.75" lower_limit="-67" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Regression and/or Elimination of Polyps at Month 3</title>
        <description>Regression and/or Elimination of Polyps from baseline to Month 3</description>
        <time_frame>Baseline and Month 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zimura + Anti-VEGF</title>
            <description>Zimura 1mg/eye intravitreal injection + Anti-VEGF (Avastin 1.25mg/eye or Lucentis 0.5mg/eye or Eylea 2mg/eye) intravitreal injection</description>
          </group>
        </group_list>
        <measure>
          <title>Regression and/or Elimination of Polyps at Month 3</title>
          <description>Regression and/or Elimination of Polyps from baseline to Month 3</description>
          <units>Polyps</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data is not available due to the limited quality of the images</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Zimura + Anti-VEGF</title>
          <description>Zimura 1mg/eye intravitreal injection + Anti-VEGF (Avastin 1.25mg/eye or Lucentis 0.5mg/eye or Eylea 2mg/eye) intravitreal injection</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institution agrees not to individually publish the results of the Study without Ophthotech's prior written consent. Institution may participate in a joint, multi-center publication of the Study results with other investigators and/or institutions only, upon the prior written consent of Ophthotech.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Keith Westby</name_or_title>
      <organization>Ophthotech Corp</organization>
      <email>Keith.Westby@ophthotech.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

